HopeStage
Back to all studies
CompletedNCT05628103

Switching from antipsychotics to SEP-363856 in schizophrenia care

About this titleRead the official source — NCT05628103

Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Anaheim and 24 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 19, 2022
Recruitment status
Completed
Enrollment listed in the registry
101
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05628103
Official title
Show the full official title

An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Anaheim · Bellflower · Culver City

19 more locations
  • Garden Grove
  • Lemon Grove
  • Riverside
  • San Diego
  • Santee
  • Torrance
  • Hollywood
  • Miami
  • Orlando
  • Atlanta
  • Chicago
  • Gaithersburg
  • St Louis
  • Las Vegas
  • Berlin
  • Charlotte
  • Hickory
  • Garfield Heights
  • Richardson

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SEP-363856.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies